What's New

January 29, 2008

BioMarck Pharmaceuticals Obtains FDA Agreement on its Phase 2 Clinical Trial Plans

October 30, 2007

BioMarck Secures Patent for Key Technology

October 24, 2007

Inhibition of Myristoylated Alanine-Rich C-Kinase Substrate Protein Markedly Inhibits Ozone-Induced Airway Inflammation

Welcome

BioMarck Pharmaceuticals, Ltd. is a privately owned biopharmaceutical company dedicated to the discovery and development of new drugs for the treatment of pulmonary diseases and disorders associated with the over-secretion of mucus and pulmonary inflammation in patients with chronic obstructive pulmonary disease (COPD), asthma and cystic fibrosis.

Expert Opinions more expert opinions

 

Press Room

BioMarck Pharmacueticals Raises $4 Million

BioWorld Today -- BioMarck Adds $4M Privately to Support Phase II Study in COPD

Dr. Kenneth Adler Receives the Prestigious O. Max Gardner Award

Watch Dr. Adler's UNC TV Webcast

COPD Will Cost U.S. $800+ Billion Over Next 20 Years, Study Predicts

Dr. Kenneth Adler wins the prestigious NIH Merit Award

Air Pollution Increases Death Risk in People with Diabetes, Heart Failure, COPD or Rheumatoid Arthritis